Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chaillon, Antoine ^a,b   Braibant, Martine ^a   Hué, Stéphane ^c   Bencharif, Samia ^a   Enard, David ^d   Moreau, Alain ^a   Samri, Assia ^e   Agut, Henri ^e   Barin, Francis ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ECOLE NORMALE SUPÉRIEURE   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLADISTICS; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRUS LOAD;

AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANTIBODIES, NEUTRALIZING; BAYES THEOREM; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LIKELIHOOD FUNCTIONS; MARKOV CHAINS; MODELS, GENETIC; MONTE CARLO METHOD; PHYLOGENY; SELECTION, GENETIC; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SURVIVORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865592592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044163     Document Type: Article

References (83)

1. Huang K-HG, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, et al. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 1: 102 doi:10.1038/ncomms1100.
2. Joos B, Fischer M, Schweizer A, Kuster H, Böni J, et al. (2007) Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions. J Infect Dis 196: 313-320 doi:10.1086/518935.
3. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83: 662-672 doi:JVI.01328-08 [pii] 10.1128/JVI.01328-08.
4. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H, (2009) Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23: 2405-2414 doi:10.1097/QAD.0b013e32833243e7.
5. Keller MA, Stiehm ER, (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13: 602-614.
6. Marasco WA, Sui J, (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25: 1421-1434 doi:10.1038/nbt1363.
7. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444 doi:10.1146/annurev-immunol-030409-101256.
8. Frost SDW, Liu Y, Pond SLK, Chappey C, Wrin T, et al. (2005) Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol. 79: 6523-6527 doi:10.1128/JVI.79.10.6523-6527.2005.
9. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149 doi:10.1073/pnas.0630530100 0630530100 [pii].
10. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312 doi:10.1038/nature01470 nature01470 [pii].
11. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85: 4828-4840 doi:10.1128/JVI.00198-11.
12. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, et al. (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7: e1001251 doi:10.1371/journal.ppat.1001251.
13. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, et al. (2006) Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20: 1923-1930 doi:10.1097/01.aids.0000247113.43714.5e 00002030-200610030-00004 [pii].
14. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, et al. (2010) Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201: 1045-1053 doi:10.1086/651144.
15. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348 doi:10.1128/JVI.00110-09.
16. Walker LM, Burton DR, (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366 doi:10.1016/j.coi.2010.02.012.
17. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR,et al. (2010) Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science. Available:http://www.ncbi.nlm.nih.gov/pubmed/20616233. Accessed 11 July 2010.
18. Bonsignori M, Hwang K-K, Chen X, Tsao C-Y, Morris L, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998-10009 doi:10.1128/JVI.05045-11.
19. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470 doi:10.1038/nature10373.
20. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, et al. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 108: 11181-11186 doi:10.1073/pnas.1103012108.
21. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
22. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189: 2167-2173 doi:10.1086/420833 JID31831 [pii].
23. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954 doi:10.1038/nm.1974.
24. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, et al. (2010) Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Comput Biol 6. Available:http://www.ncbi.nlm.nih.gov/pubmed/20949103. Accessed 17 October 2010.
25. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870 doi:10.1038/nm.1949.
26. Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, et al. (2004) Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol 78: 12625-12637 doi:10.1128/JVI.78.22.12625-12637.2004.
27. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598 doi:10.1371/journal.ppat.1000598.
28. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5: e1000594 doi:10.1371/journal.ppat.1000594.
29. Williamson S, (2003) Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol 20: 1318-1325 doi:10.1093/molbev/msg144.
30. Williamson S, Perry SM, Bustamante CD, Orive ME, Stearns MN, et al. (2005) A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients. Mol Biol Evol 22: 456-468 doi:10.1093/molbev/msi029.
31. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM, (2010) Viral evolution and escape during acute HIV-1 infection. J Infect Dis 202Suppl 2: S309-314 doi:10.1086/655653.
32. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022 doi:10.1126/science.1093137.
33. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105: 7552-7557 doi:10.1073/pnas.0802203105.
34. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952-3970 doi:10.1128/JVI.02660-07.
35. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289 doi:10.1084/jem.20090378.
36. Montefiori DC, Mascola JR, (2009) Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 4: 347-351 doi:10.1097/COH.0b013e32832f4a4d.
37. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H, (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82: 7932-7941 doi:JVI.00757-08 [pii] 10.1128/JVI.00757-08.
38. Bunnik EM, van Gils MJ, Lobbrecht MSD, Pisas L, van Nuenen AC, et al. (2009) Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Virology 390: 348-355 doi:10.1016/j.virol.2009.05.028.
39. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, et al. (2006) Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80: 6155-6164 doi:80/12/6155 [pii] 10.1128/JVI.00093-06.
40. Braibant M, Agut H, Rouzioux C, Costagliola D, Autran B, et al. (2008) Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. J Acquir Immune Defic Syndr 47: 274-284 doi:10.1097/QAI.0b013e318162cac2.
41. Braibant M, Xie J, Samri A, Agut H, Autran B, et al. (2010) Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 405: 81-92 doi:10.1016/j.virol.2010.05.026.
42. Chaillon A, Braibant M, Moreau T, Thenin S, Moreau A, et al. (2011) The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J Virol 85: 3642-3648 doi:10.1128/JVI.02424-10.
43. Connor RI, Chen BK, Choe S, Landau NR, (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944 doi:S0042-6822(85)71016-1 [pii] 10.1006/viro.1995.1016.
44. Montefiori DC, (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: 395-405 doi:10.1007/978-1-59745-170-3_26.
45. Barin F, Brunet S, Brand D, Moog C, Peyre R, et al. (2004) Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J Infect Dis 189: 322-327 doi:JID30844 [pii] 10.1086/380099.
46. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
47. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
48. Katoh K, Asimenos G, Toh H, (2009) Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol 537: 39-64 doi:10.1007/978-1-59745-251-9_3.
49. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14: 1229-1246 doi:10.1093/glycob/cwh106.
50. Kosakovsky Pond SL, Frost SDW, (2005) Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 22: 1208-1222 doi:10.1093/molbev/msi105.
51. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SDW, (2006) Automated phylogenetic detection of recombination using a genetic algorithm. Mol Biol Evol 23: 1891-1901 doi:10.1093/molbev/msl051.
52. Yang Z, (2007) PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol 24: 1586-1591 doi:10.1093/molbev/msm088.
53. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ, (2008) Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 5: e50 doi:10.1371/journal.pmed.0050050.
54. Gouy M, Guindon S, Gascuel O, (2010) SeaView Version 4: A Multiplatform Graphical User Interface for Sequence Alignment and Phylogenetic Tree Building. Molecular Biology and Evolution 27: 221-224 doi:10.1093/molbev/msp259.
55. Drummond AJ, Rambaut A, (2007) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7: 214 doi:10.1186/1471-2148-7-214.
56. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452 doi:10.1128/JVI.02108-09.
57. Doores KJ, Fulton Z, Huber M, Wilson IA, Burton DR, (2010) Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84: 10690-10699 doi:10.1128/JVI.01110-10.
58. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343 doi:10.1038/nature10696.
59. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 doi:1178746 [pii] 10.1126/science.1178746.
60. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
61. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
62. Lemey P, Kosakovsky Pond SL, Drummond AJ, Pybus OG, Shapiro B, et al. (2007) Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol 3: e29 doi:06-PLCB-RA-0364R2 [pii] 10.1371/journal.pcbi.0030029.
63. Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, et al. (2010) HIV-1 envelope subregion length variation during disease progression. PLoS Pathog 6: e1001228 doi:10.1371/journal.ppat.1001228.
64. Sagar M, Wu X, Lee S, Overbaugh J, (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598 doi:10.1128/JVI.00141-06.
65. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, et al. (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 5: e12303 doi:10.1371/journal.pone.0012303.
66. Goonetilleke N, Liu MKP, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272 doi:10.1084/jem.20090365.
67. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, et al. (2011) Demographic Processes Affect HIV-1 Evolution in Primary Infection before the Onset of Selective Processes. J Virol 85: 7523-7534 doi:10.1128/JVI.02697-10.
68. Novitsky V, Wang R, Margolin L, Baca J, Rossenkhan R, et al. (2011) Transmission of single and multiple viral variants in primary HIV-1 subtype C infection. PLoS ONE 6: e16714 doi:10.1371/journal.pone.0016714.
69. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, et al. (2011) Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins. J Virol 85: 8514-8527 doi:10.1128/JVI.00736-11.
70. Frost SDW, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 102: 18514-18519 doi:10.1073/pnas.0504658102.
71. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
72. Wu X, Wang C, O'Dell S, Li Y, Keele BF, et al. (2012) Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 86: 5844-5856 doi:10.1128/JVI.07139-11.
73. van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, et al. (2011) Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J Virol 85: 6986-6995 doi:10.1128/JVI.00268-11.
74. van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, et al. (2011) Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. J Virol 85: 8443-8448 doi:10.1128/JVI.05214-11.
75. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2008) The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82: 1860-1869 doi:JVI.02187-07 [pii] 10.1128/JVI.02187-07.
76. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359 doi:10.1128/JVI.01839-06.
77. Kirchherr JL, Hamilton J, Lu X, Gnanakaran S, Muldoon M, et al. (2011) Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409: 163-174 doi:10.1016/j.virol.2010.09.031.
78. Mens H, Kearney M, Wiegand A, Shao W, Schønning K, et al. (2010) HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 84: 12971-12981 doi:10.1128/JVI.00387-10.
79. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, et al. (2010) Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 84: 7018-7028 doi:10.1128/JVI.00548-10.
80. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
81. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
82. Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, et al. (2010) Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405: 492-504 doi:10.1016/j.virol.2010.06.029.
83. Varela M, Landskron L, Lai RPJ, McKinley TJ, Bogers WM, et al. (2011) Molecular evolution analysis of the Human Immunodeficiency Virus type 1 envelope in SHIV-infected macaques: implications for challenge dose selection. J Virol. Available:http://www.ncbi.nlm.nih.gov/pubmed/21795341. Accessed 12 August 2011.